Vanden Eynden et al.
JOCArticle
145.3; IR (KBr): 3292, 3267, 3066, 3006, 2925, 2851, 2716, 1606,
1514, 1466, 1273, 1214, 1110, 1028, 846, 806. HRMS (ESI): calcd
for C16H25NO2 [M þ H]þ 264.1958, found 264.1959.
Calcium 1,1,1,3,3,3-hexafluoroisopropoxide (75.0 mg, 0.200 mmol,
20.0 mol %) was reacted with 3-hydroxyphenethylamine
(138 mg, 1.01 mmol) and cyclohexanone (99.4 mg, 1.01 mmol)
in toluene (10 mL) for 24 h at 100 °C to give the product 14
(170 mg, 0.781 mmol, 78%) as an off-white crystalline solid.
1H NMR (400 MHz, DMSO): δ 1.17-1.25 (m, 1H), 1.40 (d, J =
12.4 Hz, 2H), 1.52-1.70 (m, 7H), 1.80 (bs, 1H), 2.53 (t, J = 5.6
Hz, 2H), 2.83 (t, J = 6.0 Hz, 2H), 6.39 (d, J = 2.0 Hz, 1H), 6.54
(dd, J = 8.4 Hz, 2.4 Hz, 1H), 7.02 (d, J = 8.8 Hz, 1H), 9.10 (bs,
1H); 13C NMR (100 MHz, DMSO): δ 21.3, 25.5, 30.5, 37.6, 37.8,
53.3, 113.1, 114.7, 126.5, 135.7, 136.1, 154.6; IR (KBr): 3305,
3049, 3028, 2925, 2861, 2532, 1606, 1502, 1456, 1257, 1242, 1232,
1145, 1123, 1066, 1034, 972, 944, 863, 850, 826, 808. HRMS
(ESI): calcd for C14H19NO [M þ H]þ 218.1539, found 218.1533.
2,3,30,40-Tetrahydro-20H-spiro[indene-1,10-isoquinolin]-60-ol (15).
The compound is prepared according to general procedure B.
Calcium 1,1,1,3,3,3-hexafluoroisopropoxide (76.1 mg, 0.203 mmol,
20.2 mol %) was reacted with 3-hydroxyphenethylamine (138
mg, 1.01 mmol) and 1-indanone (151 mg, 1.14 mmol) in toluene
(10 mL) for 24 h at 100 °C to give the product 15 (175 mg, 0.696
1-Methyl-1-phenyl-6-hydroxy-1,2,3,4-tetrahydroisoquinoline
(10). The compound is prepared using general procedure A.
Calcium 1,1,1,3,3,3-hexafluoroisopropoxide (75.0 mg, 0.200
mmol) was reacted with 3-hydroxyphenethylamine (137 mg,
1.00 mmol) and acetophenone (129 mg, 1.07 mmol) in toluene
(10 mL) for 24 h at 100 °C to give the product 10 (156 mg, 0.650
mmol, 65%) as a white solid. 1H NMR (400 MHz, DMSO): δ
1.65 (s, 3H), 2.54-2.60 (m, 2H), 2.68-2.76 (m, 1H), 2.80-2.85
(m, 1H), 6.50 (s, 1H), 6.56 (dd, J = 8.4 Hz, 2.0 Hz, 1H), 6.87
(d, J = 8.4 Hz, 1H), 7.11-7.14 (m, 1H), 7.19-7.22 (m, 4H), 9.13
(bs, 1H); 13C NMR (100 MHz, DMSO): δ 29.7, 30.4, 38.4, 58.1,
112.8, 114.9, 125.8, 127.0, 127.5, 128.4, 132.7, 136.3, 149.7,
155.1; IR (KBr): 3294, 3231, 3055, 3023, 2990, 2964, 2931,
2583, 1605, 1579, 1500, 1444, 1373, 1351, 1295, 1245, 1186,
1162, 1138, 1084, 1028, 977, 868, 843, 822, 769, 706. HRMS
(ESI): calcd for C16H17NO [M þ H]þ 240.1383, found 240.1372.
1,1-Dimethyl-6-hydroxy-1,2,3,4-tetrahydroisoquinoline (11).
The compound is prepared according to general procedure A.
Calcium 1,1,1,3,3,3-hexafluoroisopropoxide (74.7 mg, 0.200
mmol, 20.0 mol %) was reacted with 3-hydroxyphenethylamine
(137 mg, 0.997 mmol) and acetone (61.8 mg, 1.06 mmol) in
toluene (10 mL) for 24 h at 100 °C to give the product 11 (152 mg,
1
mmol, 69%) as a gray solid. H NMR (400 MHz, DMSO): δ
2.21-2.33 (m, 3H), 2.61-2.66 (m, 1H), 2.77-3.08 (m, 5H), 6.42-
6.48 (m, 3H), 6.79 (d, J = 7.6 Hz, 1H), 7.08 (t, J = 7.2 Hz, 1H),
7.17 (td, J = 7.2 Hz, 1.2 Hz, 1H), 7.26 (d, J = 7.2 Hz, 1H), 9.08
(bs, 1H); 13C NMR (125 MHz, DMSO, relaxation time = 5 s): δ
29.5, 29.8, 39.5, 42.4, 67.6, 113.3, 114.4, 124.3, 124.3, 126.1,
127.0, 128.1, 132.7, 136.6, 143.5, 150.8, 155.0; IR (KBr): 3386,
3265, 3066, 3018, 2939, 2855, 2588, 1607, 1456, 1360, 1304, 1252,
1156, 765. HRMS (ESI): calcd for C17H17NO [M þ H]þ
252.1383, found 252.1394.
1-Methyl-1-(3-methoxyphenyl)-6-hydroxy-1,2,3,4-tetrahydro-
isoquinoline (16). The compound is prepared according to general
procedure A. Calcium 1,1,1,3,3,3-hexafluoroisopropoxide (76.0
mg, 0.203 mmol, 20.0 mol %) was reacted with 3-hydroxyphe-
nethylamine (141 mg, 1.03 mmol) and 30-methoxyacetophenone
(156 mg, 1.04 mmol) in toluene (10 mL) for 24 h at 100 °C to give
the product 16 (189 mg, 0.701 mmol, 68%) as an off-white solid.
1H NMR (400 MHz, DMSO): δ 1.62 (s, 3H), 2.53-2.59 (m, 2H),
2.68-2.73 (m, 1H), 2.80-2.82 (m, 1H), 3.68 (s, 3H), 6.49 (s, 1H),
6.55 (dd, J = 2.8 Hz, 8.4 Hz, 1H), 6.71-6.73 (m, 1H), 6.77 (s,
2H), 6.90 (d, J = 8.4 Hz, 1H), 7.13 (t, J = 8.0 Hz, 1H), 9.15 (bs,
1H); 13C NMR (100 MHz, DMSO): δ 29.6, 30.4, 38.4, 54.8, 58.1,
110.5, 112.7, 113.5, 114.8, 119.4, 128.3, 128.4, 132.6, 136.2,
151.5, 155.1, 158.7; IR (KBr): 3276, 3245, 3000, 2961, 2931,
2588, 1606, 1582, 1486, 1451, 1430, 1293, 1254, 1163, 1040, 858,
826, 786, 705. HRMS (ESI): calcd for C17H19NO2 [M þ H]þ
270.1489, found 270.1485.
1
0.857 mmol, 86%) as an off-white solid. H NMR (400 MHz,
DMSO): δ 1.28 (s, 6H), 2.56 (t, J = 5.6 Hz, 2H), 2.90 (t, J =
5.6 Hz, 2H), 6.398 (s, 1H), 6.52 (d, J = 1.6 Hz, 1H), 6.99 (d, J =
8.4 Hz, 1H); 13CNMR(100MHz, DMSO):δ30.4, 31.1, 38.4, 51.9,
113.2, 114.7, 126.6, 134.9, 135.4, 154.73; IR (KBr): 3415, 3261,
3038, 3016, 2972, 2951, 3797, 2694, 2610, 1618, 1582, 1498, 1367,
1264, 1256, 1242, 1158, 1127, 1088, 1061, 991, 868, 812. HRMS
(ESI): calcd for C11H15NO [M þ H]þ 178.1226, found 178.1221.
1-Methyl-1-phenethyl-6-hydroxy-1,2,3,4-tetrahydroisoquinoline
(12). The compound is prepared according to general procedure
A. Calcium 1,1,1,3,3,3-hexafluoroisopropoxide (75.8 mg, 0.203
mmol, 20.3 mol %) was reacted with 3-hydroxyphenethylamine
(137 mg, 1.00 mmol) and benzylacetone (148 mg, 1.00 mmol) in
toluene (10 mL) for 24 h at 100 °C to give the product 12 (210 mg,
1
0.784 mmol, 78%) as an off-white crystalline solid. H NMR
(400 MHz, DMSO): δ 1.31 (s, 3H), 1.76 (td, J = 12.8 Hz, 4.8 Hz,
1H), 2.00 (td, J = 13.6 Hz, 4.4 Hz, 1H), 2.30 (td, J = 12.6 Hz,
4.0 Hz, 1H), 2.50-2.52 (m, 1H), 2.53-2.68 (m, 2H), 2.94 (t, J =
5.2 Hz, 2H), 6.44 (d, J = 2.8 Hz, 1H), 6.58 (dd, J = 8.4 Hz,
2.4 Hz, 1H), 7.02 (d, J = 8.8 Hz, 1H), 7.11 (dd, J = 9.2 Hz,
6.8 Hz, 3H), 7.20-7.24 (m, 2H); 13C NMR (100 MHz, DMSO):
δ 29.2, 30.0, 30.5, 38.4, 45.0, 54.5, 113.3, 114.7, 125.3, 126.6,
128.1, 133.9, 136.2, 143.1, 154.6; IR (KBr) 3274, 3232, 3022,
2946, 2681, 2580, 1602, 1577, 1496, 1453, 1379, 1350, 1296, 1250,
1159, 1114, 881, 855, 817, 754, 702. HRMS (ESI): calcd for
C18H21NO [M þ H]þ 268.1696, found 268.1682.
1-Methyl-1-(4-nitrophenyl)-6-hydroxy-1,2,3,4-tetrahydroiso-
quinoline (17). The compound is prepared according to general
procedure B. Calcium 1,1,1,3,3,3-hexafluoroisopropoxide (75.9
mg, 0.203 mmol, 20.0 mol %) was reacted with 3-hydroxyphe-
nethylamine (141 mg, 1.02 mmol) and 40-nitroacetophenone
(182 mg, 1.10 mmol) in toluene (10 mL) for 24 h at 100 °C to
give the product 17 (246 mg, 0.865 mmol, 84%) as a brown-red
solid. 1H NMR (400 MHz, DMSO): δ 1.67 (s, 3H), 2.48-2.53
(m, 1H), 2.66-2.73 (m, 2H), 2.83-2.86 (m, 1H), 6.50 (s, 1H),
6.55 (dd, J = 8.4 Hz, 2.4 Hz, 1H), 6.88 (d, J = 8.4 Hz, 1H), 7.49
30,40-Dihydro-20H-spiro[cyclopentane-1,10-isoquinolin]-60-ol (13).
The compound is prepared according to general procedure A.
Calcium 1,1,1,3,3,3-hexafluoroisopropoxide (75.8 mg, 0.207
mmol, 20.5 mol %) was reacted with 3-hydroxyphenethylamine
(139 mg, 1.01 mmol) and cyclopentanone (93.5 mg, 1.11 mmol)
in toluene (10 mL) for 24 h at 100 °C to give the product 13 (150
mg, 0.740 mmol, 73%) as a tan solid. 1H NMR (400 MHz,
DMSO): δ 1.69-1.77 (m, 8H), 2.55 (t, J = 5.6 Hz, 2H), 2.83
(t, J = 5.6 Hz, 2H), 6.37 (s, 1H), 6.53 (dd, J = 2.4 Hz, 8.2 Hz,
1H), 6.95 (d, J = 8.4 Hz, 1H), 9.08 (bs, 1H); 13C NMR (100
MHz, DMSO, relaxation time = 10 s): δ 24.5, 30.3, 39.4, 42.4,
63.6, 113.4, 114.4, 126.6, 134.1, 136.4, 154.5; IR (KBr): 3260,
3021, 2949, 2872, 2790, 2701, 2611, 1618, 1581, 1498, 1117, 853,
807. HRMS (ESI): calcd for C13H17NO [M þ H]þ 204.1383, found
204.1391.
(d, J = 8.8 Hz, 2H), 8.07 (d, J = 8.8 Hz, 2H), 9.19 (bs, 1H); 13
C
NMR (100 MHz, DMSO): δ 29.5, 29.9, 38.5, 58.3, 113.1, 115.1,
122.7, 128.3, 131.6, 136.4, 145.7, 155.5, 157.8; IR (KBr): 3265,
3252, 3109, 3054, 2979, 2939, 2695, 1604, 1579, 1517, 1500, 1464,
1351, 1296, 1250, 1111, 1068, 855, 818, 789, 755, 699. HRMS
(ESI): calcd for C16H15N2O3 [M þ H]þ 285.1234, found 285.1226.
1-Methyl-1-(ethylcarboxylate)-6-hydroxy-1,2,3,4-tetrahydro-
isoquinoline (18). The compound is prepared according to general
procedure A. Calcium 1,1,1,3,3,3-hexafluoroisopropoxide (75.8 mg,
0.203 mmol, 20.1 mol %) was reacted with 3-hydroxyphenethyla-
mine (138 mg, 1.01 mmol) and ethyl pyruvate (140 mg, 1.20 mmol)
30,40-Dihydro-20H-spiro[cyclohexane-1,10-isoquinolin]-60-ol (14).
The compound is prepared according to general procedure A.
8548 J. Org. Chem. Vol. 75, No. 24, 2010